Proposed Nasdaq Listing: CAT Makes Public Filing With SEC

Apr 04, 2001, 01:00 ET from Cambridge Antibody Technology

    MELBOURN, England, April 4 /PRNewswire/ -- Cambridge Antibody Technology
 (LSE: CAT) announces that it has now made a public filing with the SEC in
 preparation for its proposed listing of ADRs on the NASDAQ market, as
 previously announced.  This filing follows an extensive period of consultation
 with the SEC.  The filing of a registration statement does not guarantee that
 CAT's ADRs will be listed at any time or at all.
 
     Notes to Editors:
 
     Cambridge Antibody Technology (LSE: CAT)
     * CAT is a UK biotechnology company using its proprietary technologies in
       human monoclonal antibodies for drug discovery and drug development.
       Based in Melbourn, 10 miles south of Cambridge, England, CAT currently
       employs around 210 people.
     * CAT's ordinary shares are listed on the London Stock Exchange.  CAT
       raised 41m pounds in its IPO in March 1997 and 93m pounds (89.4m pounds
       net of expenses) in a secondary offering in March 2000.
     * CAT has an advanced platform technology for rapidly isolating human
       monoclonal antibodies, primarily using phage display technology.  CAT's
       library currently incorporates around 100 billion distinct antibodies.
       This library forms the basis for the company's strategy to develop a
       portfolio of clinical development programmes and for discovering new
       drug leads using functional genomics.  Four human therapeutic antibodies
       developed by CAT are at various stages of clinical trials.
     * CAT works in partnership with other companies at all stages of the drug
       discovery and development process.  CAT's collaborations, past and
       present, include: AstraZeneca, Knoll AG, Eli Lilly, Genentech, Genetics
       Institute, Genzyme, Human Genome Sciences, Immunex, Oxford
       GlycoSciences, Pharmacia, Pfizer, Wyeth-Ayerst and Zyomyx.
 
 

SOURCE Cambridge Antibody Technology
    MELBOURN, England, April 4 /PRNewswire/ -- Cambridge Antibody Technology
 (LSE: CAT) announces that it has now made a public filing with the SEC in
 preparation for its proposed listing of ADRs on the NASDAQ market, as
 previously announced.  This filing follows an extensive period of consultation
 with the SEC.  The filing of a registration statement does not guarantee that
 CAT's ADRs will be listed at any time or at all.
 
     Notes to Editors:
 
     Cambridge Antibody Technology (LSE: CAT)
     * CAT is a UK biotechnology company using its proprietary technologies in
       human monoclonal antibodies for drug discovery and drug development.
       Based in Melbourn, 10 miles south of Cambridge, England, CAT currently
       employs around 210 people.
     * CAT's ordinary shares are listed on the London Stock Exchange.  CAT
       raised 41m pounds in its IPO in March 1997 and 93m pounds (89.4m pounds
       net of expenses) in a secondary offering in March 2000.
     * CAT has an advanced platform technology for rapidly isolating human
       monoclonal antibodies, primarily using phage display technology.  CAT's
       library currently incorporates around 100 billion distinct antibodies.
       This library forms the basis for the company's strategy to develop a
       portfolio of clinical development programmes and for discovering new
       drug leads using functional genomics.  Four human therapeutic antibodies
       developed by CAT are at various stages of clinical trials.
     * CAT works in partnership with other companies at all stages of the drug
       discovery and development process.  CAT's collaborations, past and
       present, include: AstraZeneca, Knoll AG, Eli Lilly, Genentech, Genetics
       Institute, Genzyme, Human Genome Sciences, Immunex, Oxford
       GlycoSciences, Pharmacia, Pfizer, Wyeth-Ayerst and Zyomyx.
 
 SOURCE  Cambridge Antibody Technology